NASDAQ: AVBP
Arrivent Biopharma Inc Stock Ownership - Who owns Arrivent Biopharma?

Insider buying vs selling

Have Arrivent Biopharma Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Hillhouse Investment Management Ltd10% Owner2025-12-10555,555$23.37
$12.98MSell
Robin LachapelleChief Operating Officer2025-07-112,050$2.28
$4.67kBuy
Robin LachapelleChief Operating Officer2025-07-112,600$2.28
$5.93kBuy
Robin LachapelleChief Operating Officer2025-07-116,503$2.28
$14.83kBuy

1 of 1

AVBP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AVBP insiders and whales buy or sell their stock.

AVBP Shareholders

What type of owners hold Arrivent Biopharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Hhlr Advisors Ltd10.86%4,484,672$96.96MInstitution
Hillhouse Investment Management Ltd9.52%3,929,117$84.95MInsider
Infinitum Asset Management LLC9.37%3,868,923$83.65MInstitution
Suvretta Capital Management LLC8.97%3,703,452$80.07MInstitution
Fmr LLC8.25%3,407,549$73.67MInstitution
Orbimed Advisors LLC7.33%3,027,328$65.45MInstitution
Blackrock Inc4.96%2,046,138$44.24MInstitution
Vanguard Group Inc4.92%2,029,531$43.88MInstitution
Octagon Capital Advisors LP4.77%1,971,054$42.61MInstitution
Novo Holdings A4.70%1,942,142$41.99MInstitution

1 of 3

AVBP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AVBP79.49%20.51%Net SellingNet Selling
CTMX81.09%13.04%Net Selling
GHRS71.79%0.00%
BBOT62.58%37.42%Net Buying
URGN81.39%18.61%Net SellingNet Selling

Arrivent Biopharma Stock Ownership FAQ

Who owns Arrivent Biopharma?

Arrivent Biopharma (NASDAQ: AVBP) is owned by 93.43% institutional shareholders, 24.11% Arrivent Biopharma insiders, and 0.00% retail investors. Hillhouse Investment Management Ltd is the largest individual Arrivent Biopharma shareholder, owning 3.93M shares representing 9.52% of the company. Hillhouse Investment Management Ltd's Arrivent Biopharma shares are currently valued at $88.09M.

If you're new to stock investing, here's how to buy Arrivent Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.